Baxter begins Phase II trials of endovascular AAA (abdominal aortic aneurysm) treatment following rivals Medtronic and Guidant
This article was originally published in Clinica
Another endovascular treatment for abdominal aortic aneurysms (AAAs) has entered trials in the US. Phase II studies of Baxter CardioVascular's Lifepath device have been approved by the FDA and around 150 patients will be treated.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.